Carprox vet 20 mg tablets for dogs

Страна: Ірландія

мова: англійська

Джерело: HPRA (Health Products Regulatory Authority)

Активний інгредієнт:

Carprofen

Доступна з:

Krka, d.d., Novo mesto

Код атс:

QM01AE91

ІПН (Міжнародна Ім'я):

Carprofen

Дозування:

20 mg/tablet

Фармацевтична форма:

Tablet

Тип рецепту:

POM: Prescription Only Medicine as defined in relevant national legislation

Терапевтична група:

Dogs

Терапевтична области:

carprofen

Терапевтичні свідчення:

N.S.A.I.D.

Статус Авторизація:

Authorised

Дата Авторизація:

2010-12-10

Характеристики продукта

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprox vet 20 mg tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Carprofen
20 mg
EXCIPIENTS:
Ferric oxide red (E172)
0.61 mg
Ferric oxide black (E172)
0.38 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet.
Round, dark brown, marbled tablets with visible darker spots, one-side
scored and bevel-edged.
The tablets can be divided into two equal parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Reduction of inflammation and pain caused by musculoskeletal disorders
and degenerative joint disease. As a follow
up to parenteral analgesia in the management of post operative pain.
4.3 CONTRAINDICATIONS
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in dogs less than 4 months of age.
Do not use in case of hypersensitivity to active substance or to any
of the excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a possibility of gastrointestinal
ulceration or bleeding, or where there is evidence of a blood
dyscrasia.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to Sections 4.3 and 4.5.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_3_
_/_
_1_
_1_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_2_
_1_
_4_
_9_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR U